2023
A proposal from the Liver Forum for the management of comorbidities in nonalcoholic steatohepatitis therapeutic trials
Raluca Pais, Bertrand Cariou, Mazen Noureddin, Sven Francque, Jörn M. Schattenberg, Manal F. Abdelmalek, Gadi Lalazar 8, Sharat Varma, Julie Dietrich, Veronica Miller, Arun Sanyal, Vlad Ratziu, on behalf of the Liver Forum NAFLD-Associated Comorbidities Working Group
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum
Melissa Palmer, David E. Kleiner, Zachary Goodman, Elizabeth Brunt, Mark I. Avigan, Arie Regev, Paul H. Hayashi, James H. Lewis, Ruby Mehta, Stephen A. Harrison, Massimo Siciliano, Charles A. McWherter, Raj Vuppalanchi, Cynthia Behling, Veronica Miller, Naga Chalasani, Arun J. Sanyal
2020
Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations from the Liver Forum
Oliver Glass, Claudia Filozof, Mazen Noureddin, Mark Berner-Hansen, Elmer Schabel, Stephanie O. Omokaro, Jörn M. Schattenberg, Katherine Barradas, Veronica Miller, Sven Francque, Manal F. Abdelmalek, on behalf of the Liver Forum Standard of Care Working Group
Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations from the Multi-stakeholder Liver Forum
Mazen Noureddin, Jean L. Chan, Katherine Barradas, Lara Dimick-Santos, Elmer Schabel, Stephanie O. Omokaro, Frank A. Anania, Robert P. Myers, Veronica Miller, Arun J. Sanyal, Naga Chalasani, on behalf of the Liver Forum NASH Cirrhosis Working Group
2019
Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease
Miriam B. Vos, Lara Dimick-Santos, Ruby Mehta, Stephanie O. Omokaro, Johannes Taminiau, Elmer Schabel, David E. Kleiner, Peter Szitanyi, Piotr Socha, Jeffrey B. Schwimmer, Stephanie Noviello, Debra G. Silberg, Richard Torstenson, Veronica Miller, Joel E. Lavine, on behalf of the Liver Forum Pediatric Working Group
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
Amanda Cheung, Brent A. Neuschwander-Tetri, David E. Kleiner, Elmer Schabel, Mary Rinella, Stephen Harrison, Vlad Ratziu, Arun J. Sanyal, Rohit Loomba, Sophie Jeannin Megnien, Richard Torstenson, Veronica Miller, on behalf of the Liver Forum Case Definitions Working Group
2018
Case definitions for inclusion and analysis of endpoints in clinical trials for NASH through the lens of regulatory science
M. Shadab Siddiqui, Stephen A. Harrison, Manal F. Abdelmalek, Quentin M. Anstee, Pierre Bedossa, Laurent Castera, Lara Dimick-Santos, Scott Friedman, Katherine Greene, David Kleiner, Sophie Megnien, Brent A. Neuschwander-Tetri, Vlad Ratziu, Elmer Schabel,Veronica Miller, Arun J. Sanyal, On behalf of the Liver Forum Case Definitions Working Group
2017
Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum
Yuval A. Patel, Joanne C. Imperial, Andrew J. Muir, Quentin M. Anstee, David DeBrota, Lara Dimick-Santos, Claudia Filozof, Ruby Mehta, Arun J. Sanyal, Elmer Schabel, Brent A. Neuschwander-Tetri, Veronica Miller, on behalf of the Liver Forum’s Data Standardization Working Group
